RTP Mobile Logo
Fourth Annual National General Medical Oncology Summit (Symposium Video Proceedings)
Released April 2025

Featuring perspectives from 36 clinical investigators. Published April 2025.

CE Information and Faculty Disclosures

  • TARGET AUDIENCE
    This program is intended for medical oncologists, hematologists, hematology-oncology fellows, surgeons, radiation oncologists, pharmacists, nurse practitioners, clinical nurse specialists and other healthcare professionals involved in the treatment of cancer.

    LEARNING OBJECTIVES

    • Effectively apply results of practice-changing clinical research to the care of patients with cancer.
    • Appraise the clinical relevance of recent pivotal cancer research published in peer-reviewed journals or presented at major oncology conferences.
    • Recall ongoing trials of therapies for select hematologic cancers and solid tumors, and appropriately refer patients for study participation.
    • Use an understanding of tumor biomarkers and single and multigene signatures to individualize the care of patients with cancer.
    • Educate patients with diverse hematologic cancers and solid tumors about the benefits and risks of new therapeutic agents and strategies.
    • Apply an awareness of new datasets and the perspectives of tumor-specific clinical investigators to refine or validate current treatment algorithms.
    • Evaluate the mechanisms of action, tolerability and efficacy of promising investigational agents, and consider the implications for clinical practice.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    Audio Program: Research To Practice designates this enduring material for a maximum of 15.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Video Program: Research To Practice designates this enduring material for a maximum of 15.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    Successful completion of these CME activities, which includes participation in the evaluation component and a post-test, enables the participant to earn up to 15.75 (audio) and 15.25 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology and hematology.

    AMERICAN BOARD OF SURGERY (ABS) — CONTINUOUS CERTIFICATION (CC)
    Successful completion of these CME activities, which includes participation in the evaluation component and a post-test, enables the learner to earn credit toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.

    Please note, these programs have been specifically designed for the following ABS practice area: complex general surgical oncology.

    PRIVACY POLICY
    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    HOW TO USE THIS CME ACTIVITY
    Audio Program: This CME activity consists of an audio component. To receive credit, the participant should review the CME information, listen to the MP3s, review the downloadable slide set, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/GMO25/CME. The corresponding video program is available as an alternative at ResearchToPractice.com/GMO25/Video.

    Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/GMO25/Video/CME. The corresponding audio program is available as an alternative at ResearchToPractice.com/GMO25.

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

    Thomas A Abrams, MD
    Institute Physician
    Dana-Farber Cancer Institute
    Assistant Professor of Medicine
    Harvard Medical School
    Director, Liver Tumor Center
    Boston, Massachusetts

    Advisory Committees: AstraZeneca Pharmaceuticals LP, Eisai Inc, HistoSonics; Consulting Agreements: Elevar Therapeutics; Contracted Research: AstraZeneca Pharmaceuticals LP.

    Rahul Aggarwal, MD
    Professor of Medicine and Thomas Perkins Distinguished Professor of Cancer Research
    Director, Genitourinary Medical Oncology
    University of California, San Francisco
    Department of Medicine
    Division of Hematology/Oncology
    Associate Director for Clinical Research
    UCSF Helen Diller Family Comprehensive Cancer Center
    San Francisco, California

    Advisory Committees: Novartis; Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, FibroGen Inc, Flare Therapeutics, Johnson & Johnson Pharmaceuticals, Merck, ORIC Pharmaceuticals, Pfizer Inc, Xencor; Contracted Research: Amgen Inc, AstraZeneca Pharmaceuticals LP, Johnson & Johnson Pharmaceuticals, Merck; Nonrelevant Financial Relationships: Prostate Cancer Clinical Trials Consortium.

    Aditya Bardia, MD, MPH
    Professor of Medicine
    Geffen School of Medicine at UCLA
    Director, Breast Oncology Program
    Assistant Chief (Translational Research)
    Division of Medical Oncology
    Director of Translational Research Integration
    UCLA Health Jonsson Comprehensive Cancer Center
    Los Angeles, California

    Consulting Agreements and Contracted Research: Alyssum Therapeutics, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Lilly, Menarini Group, Merck, Novartis, Pfizer Inc, Sanofi.

    Mitesh J Borad, MD
    Professor of Medicine
    Mayo Clinic College of Medicine and Science
    Getz Family Professor of Research
    Mayo Clinic Arizona
    Program Leader, Novel Therapeutics and Therapeutic Modalities Program
    Mayo Clinic Comprehensive Cancer Center
    Phoenix, Arizona

    Advisory Committees: Elevar Therapeutics; Consulting Agreements: Guardant Health, Jazz Pharmaceuticals Inc; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, Biond Biologics, Dragonfly Therapeutics, Eisai Inc, Elevation Oncology, Incyte Corporation, Kinnate Biopharma, Nuvectis Pharma Inc, Pfizer Inc, Relay Therapeutics, Revolution Medicines, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC; Data and Safety Monitoring Boards/Committees: Accession Therapeutics.

    Virginia F Borges, MD, MMSc
    Professor of Medicine with Tenure
    Robert F and Patricia Young-Connor Endowed Chair in Young Women’s Breast Cancer Research
    Deputy Head, Division of Medical Oncology
    Director, Breast Cancer Research Program and Young Women’s Breast Cancer Translational Program
    University of Colorado Cancer Center
    Aurora, Colorado

    Advisory Committees: AstraZeneca Pharmaceuticals LP, Gilead Sciences Inc, Olema Oncology, Pfizer Inc, Seagen Inc; Consulting Agreements: Gilead Sciences Inc, Olema Oncology; Contracted Research: Agendia Inc, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Gilead Sciences Inc, Olema Oncology, Pfizer Inc, Seagen Inc; Data and Safety Monitoring Boards/Committees: Pfizer Inc, Seagen Inc (HER2CLIMB-02 trial); Nonrelevant Financial Relationships: Pearl Scientific LLC.

    Prithviraj Bose, MD
    Professor, Department of Leukemia
    Co-Leader, Section of Myeloproliferative Neoplasms
    Division of Cancer Medicine
    The University of Texas MD Anderson Cancer Center
    Houston, Texas

    Advisory Committees: Blueprint Medicines, Geron Corporation, GSK, Karyopharm Therapeutics, Keros Therapeutics, PharmaEssentia, Sumitomo Dainippon Pharma Oncology Inc; Consulting Agreements: AbbVie Inc, Blueprint Medicines, Bristol Myers Squibb, Cogent Biosciences, CTI BioPharma, a Sobi Company, Disc Medicine, Geron Corporation, GSK, Incyte Corporation, Ionis Pharmaceuticals Inc, Jubilant Pharma Limited, Karyopharm Therapeutics, Keros Therapeutics, Morphic Therapeutic, MorphoSys, Novartis, Ono Pharmaceutical Co Ltd, PharmaEssentia, RayThera, Sumitomo Dainippon Pharma Oncology Inc; Contracted Research: Ajax Therapeutics, Blueprint Medicines, Bristol Myers Squibb, Cogent Biosciences, CTI BioPharma, a Sobi Company, Disc Medicine, GSK, Incyte Corporation, Ionis Pharmaceuticals Inc, Janssen Biotech Inc, Kartos Therapeutics, Karyopharm Therapeutics, MorphoSys, Sumitomo Dainippon Pharma Oncology Inc, Telios Pharma Inc.

    Harold J Burstein, MD, PhD
    Institute Physician
    Dana-Farber Cancer Institute
    Professor of Medicine
    Harvard Medical School
    Boston, Massachusetts

    No relevant conflicts of interest to disclose.

    Natalie S Callander, MD
    Director, Myeloma Clinical Program
    University of Wisconsin Carbone Cancer Center
    Madison, Wisconsin

    No relevant conflicts of interest to disclose.

    Rashmi Chugh, MD
    Professor of Internal Medicine
    Division of Hematology/Oncology
    Rogel Comprehensive Cancer Center
    University of Michigan
    Ann Arbor, Michigan

    Advisory Committees: Deciphera Pharmaceuticals Inc, Inhibrx, Recordati, SpringWorks Therapeutics Inc.

    Christopher Flowers, MD, MS
    Division Head, Division of Cancer Medicine
    Chair, Professor, Department of Lymphoma/Myeloma
    John Brooks Williams and Elizabeth Williams Distinguished University Chair in Cancer Medicine
    The University of Texas MD Anderson Cancer Center
    Houston, Texas

    Consulting Agreements: AbbVie Inc, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Celgene Corporation, Denovo Biopharma, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Karyopharm Therapeutics; Contracted Research: 4D Pharma PLC, AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Alaunos Therapeutics, Allogene Therapeutics, Amgen Inc, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Cellectis, EMD Serono Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Guardant Health, Iovance Biotherapeutics, Janssen Biotech Inc, Kite, A Gilead Company, MorphoSys, Nektar Therapeutics, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Sanofi, Takeda Pharmaceuticals USA Inc, TG Therapeutics Inc, Xencor; Nonrelevant Financial Relationships: Burroughs Wellcome Fund, Cancer Prevention and Research Institute of Texas (CPRIT Scholar in Cancer Research), Eastern Cooperative Oncology Group, Foresight Diagnostics, National Cancer Institute, N-Power Medicine Inc, V Foundation.

    Jonathan Goldman, MD
    Associate Professor, UCLA Hematology and Oncology
    Director of Clinical Trials in Thoracic Oncology
    UCLA Health
    Santa Monica, California

    Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, a member of the Roche Group, Gilead Sciences Inc, Gritstone bio, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Pfizer Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc; Contracted Research: AbbVie Inc, Advaxis Inc,AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, a member of the Roche Group, GSK, Janssen Biotech Inc, Lilly, Merck, Pfizer Inc, Puma Biotechnology Inc, Spectrum Pharmaceuticals Inc, Vaccinex Inc.

    Ramaswamy Govindan, MD
    Professor of Medicine
    Director, Section of Oncology
    Anheuser-Busch Endowed Chair in Medical Oncology
    Washington University School of Medicine
    St Louis, Missouri

    No relevant conflicts of interest to disclose.

    Shilpa Gupta, MD
    Clinical Professor of Medicine
    Cleveland Clinic Lerner College of Medicine
    Case Western Reserve University
    Director, Genitourinary Oncology Program
    Taussig Cancer Institute, Cleveland Clinic
    Cleveland, Ohio

    Consulting Agreements: Astellas, Bristol Myers Squibb, Gilead Sciences Inc, Janssen Biotech Inc, Merck, Novartis, Pfizer Inc; Contracted Research: Acrivon Therapeutics, Bristol Myers Squibb, Convergent Therapeutics Inc, Flare Therapeutics, Merck, Novartis, Roche Laboratories Inc, Tyra Biosciences Inc; Data and Safety Monitoring Boards/Committees: Protara Therapeutics; Speakers Bureaus: Bristol Myers Squibb; Stock Options/Stock — Public Companies: BioNTech SE, Nektar Therapeutics.

    Yelena Y Janjigian, MD
    Chief of Gastrointestinal Oncology Service
    Department of Medicine
    Memorial Sloan Kettering Cancer Center
    New York, New York

    Advisory Committees: AbbVie Inc, AmerisourceBergen, Arcus Biosciences, ARS Pharmaceuticals, AskGene Pharma, Astellas, AstraZeneca Pharmaceuticals LP, Basilea Pharmaceutica Ltd, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Daiichi Sankyo Inc, eChinaHealth, Eisai Inc, Geneos Therapeutics, GSK, Guardant Health, HC Wainwright & Co, Imugene, Inspirna, Lilly, Lynx Health, Merck, Merck Serono, Mersana Therapeutics Inc, PeerMD, Pfizer Inc, Sanofi, Seagen Inc, Silverback Therapeutics, Suzhou Liangyihui Network Technology Co Ltd, Zymeworks Inc; Contracted Research: Arcus Biosciences, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Genentech, a member of the Roche Group, Inspirna, Lilly, Merck, Transcenta; Stock Options — Private Companies: Inspirna; Nonrelevant Financial Relationships: Clinical Care Options, Cycle for Survival, ED Medresources Inc, Fred’s Team, Imedex, Master Clinician Alliance, MJH Life Sciences, National Cancer Institute, Paradigm Medical Communications, PeerView Institute, Physician Education Resource (PER), Stand Up 2 Cancer, Talem Health, TotalCME, US Department of Defense, Veda Life Sciences Inc (stock options), WebMD.

    Ahmed Omar Kaseb, MD, CMQ
    John E and Dorothy J Harris Professor in Gastrointestinal Cancer Research
    Member, National Hepatobiliary Task Force, NCI, USA
    Tenured Professor and Director, Hepatocellular Carcinoma Program
    Director, MD Anderson HCC SPORE
    Editor-in-Chief, Journal of Hepatocellular Carcinoma
    Department of Gastrointestinal Medical Oncology
    The University of Texas MD Anderson Cancer Center
    Houston, Texas

    Advisory Committees, Consulting Agreements and Contracted Research: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Eisai Inc, Exelixis Inc, Genentech, a member of the Roche Group, Merck, Roche Laboratories Inc.

    Samuel J Klempner, MD
    Associate Professor
    Massachusetts General Hospital
    Harvard Medical School
    Boston, Massachusetts

    Advisory Committees: Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology, Gilead Sciences Inc, I-Mab Biopharma, Merck, Mersana Therapeutics Inc, Natera Inc, Novartis, Pfizer Inc, Taiho Oncology Inc; Consulting Agreements: Astellas, Novartis (ended 2023); Stock Options — Private Companies: MBrace Therapeutics; Nonrelevant Financial Relationships: Debbie's Dream Foundation, Degregorio Family Foundation, Gastric Cancer Foundation, Gateway for Cancer Research, National Cancer Institute/National Institutes of Health, NCCN (member of Gastric and Esophageal Guidelines Committees), Stand Up 2 Cancer/AACR, Torrey Coast Foundation.

    Andrew T Kuykendall, MD
    Associate Member, Department of Malignant Hematology
    Moffitt Cancer Center
    Associate Professor, Department of Oncologic Sciences
    University of South Florida
    Tampa, Florida

    Advisory Committees: AbbVie Inc, Blueprint Medicines, Bristol Myers Squibb, Cogent Biosciences, CTI BioPharma, a Sobi Company, Incyte Corporation, Karyopharm Therapeutics, PharmaEssentia; Consulting Agreements: AbbVie Inc, Karyopharm Therapeutics, MorphoSys; Contracted Research: Blueprint Medicines, Bristol Myers Squibb, Geron Corporation, Janssen Biotech Inc, Protagonist Therapeutics, MorphoSys; Data and Safety MonitoringBoard/Committees: Geron Corporation.

    Nicole Lamanna, MD
    Judy Horrigan Professor of Medicine
    Director of the Chronic Lymphocytic Leukemia Program
    Leukemia Service, Hematologic Malignancies Section
    Herbert Irving Comprehensive Cancer Center
    NewYork-Presbyterian/Columbia University Irving Medical Center
    New York, New York

    Advisory Committees: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd,Genmab US Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company; Contracted Research (Institutional Research/Grant Support): AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Genentech, a member of the Roche Group, Genmab US Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MingSight Pharmaceuticals, Octapharma, Oncternal Therapeutics; Honoraria: AbbVie Inc, Aptitude Health, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Curio Science, DAVA Oncology, Genmab US Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company; Nonrelevant Financial Relationships: Bio Ascend, Clinical Care Options, OncLive, PeerView, Physician Education Resource (PER), Targeted Oncology.

    Natasha B Leighl, MD, MMSc (Clin Epi)
    Professor, Department of Medicine
    Adjunct Professor, IHPME, Dalla Lana School of Public Health
    University of Toronto
    OSI Pharmaceuticals Foundation Chair in New Cancer Drug Development
    Thoracic Oncology Lead, Division of Medical Oncology
    Princess Margaret Cancer Center
    Toronto, Ontario, Canada

    No relevant conflicts of interest to disclose.

    Christopher Lieu, MD
    Professor of Medicine
    Associate Director for Clinical Research
    Co-Director, GI Medical Oncology
    University of Colorado Cancer Center
    Aurora, Colorado

    Consulting Agreements: Amgen Inc, Pfizer Inc; Contracted Research: Genentech, a member of the Roche Group, Sanofi.

    Stephen V Liu, MD
    Associate Professor of Medicine
    Georgetown University Hospital
    Washington, DC

    Advisory Committees: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc,Genentech, a member of the Roche Group, Gilead Sciences Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson Pharmaceuticals; Consulting Agreements: AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, GSK, Guardant Health, Jazz Pharmaceuticals Inc, Johnson & Johnson Pharmaceuticals, Lilly, Merck, Merus, Mirati Therapeutics Inc, Natera Inc, Novartis, OSE Immunotherapeutics, Pfizer Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines, Takeda Pharmaceuticals USA Inc, Yuhan Corporation; Contracted Research: AbbVie Inc, Alkermes, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Cogent Biosciences, Duality Biologics, Elevation Oncology, Ellipses Pharma, Genentech, a member of the Roche Group, Gilead Sciences Inc, Merck, Merus, Nuvalent, OSE Immunotherapeutics, Puma Biotechnology Inc, RAPT Therapeutics, Synthekine, SystImmune Inc.

    Amit Mahipal, MD, MPH
    Professor
    Case Western Reserve University
    Director, GI Oncology
    UH Seidman Cancer Center
    Cleveland, Ohio

    No relevant conflicts of interest to disclose.

    Thomas Martin, MD
    Associate Chief, Hematology/Oncology
    Director, Hematology, Blood and Marrow Transplantation and Cell Therapy
    Helen Diller Family Comprehensive Cancer Center
    UCSF Medical Center
    San Francisco, California

    Consulting Agreements: GSK, Lilly, Pfizer Inc; Contracted Research: Amgen Inc, Bristol Myers Squibb, Johnson & Johnson Pharmaceuticals, Sanofi; Data and Safety MonitoringBoards/Committees: Lilly.

    Paul E Oberstein, MD, MS
    Associate Professor of Medicine
    Section Chief, Gastrointestinal Medical Oncology
    Co-Director, Pancreatic Disease Center
    Perlmutter Comprehensive Cancer Center
    New York, New York

    Advisory Committees: Boehringer Ingelheim Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Merck; Consulting Agreements: Ipsen Biopharmaceuticals Inc; Speakers Bureaus: Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc.

    William K Oh, MD
    Director of Precision Medicine
    Yale Cancer Center
    Professor of Medicine, Division of Medical Oncology
    Yale School of Medicine
    Medical Director, Service Line
    Smilow Cancer Hospital at Greenwich Hospital
    New Haven, Connecticut

    Advisory Committees: Pfizer Inc; Consulting Agreements: Abbott Laboratories, AstraZeneca Pharmaceuticals LP, Cytogen Corporation, Nature's Toolbox Inc, Novartis, Sumitomo Dainippon Pharma Oncology Inc; Stock Options — Private Companies: Nature’s Toolbox Inc; Stock Options/Stock —Public Companies: GeneDx.

    David M O'Malley, MD
    Director and Professor
    Division of Gynecologic Oncology in Obstetrics and Gynecology
    John G Boutselis Chair in Gynecologic Oncology
    The Ohio State University and The James Comprehensive Cancer Center
    Columbus, Ohio

    Advisory Committees and Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Corcept Therapeutics, Duality Biologics, Genmab US Inc, GSK, Merck, MSD, Regeneron Pharmaceuticals Inc, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Sutro Biopharma, Verastem Inc; Contracted Research: AbbVie Inc, Adaptimmune, Advaxis Inc, Agenus Inc, Alkermes, Aravive Inc, Arcus Biosciences, Arquer Diagnostics, AstraZeneca Pharmaceuticals LP, Atossa Therapeutics, BeiGene Ltd, Bristol Myers Squibb, Cardiff Oncology, Celcuity, Clovis Oncology, Corcept Therapeutics, Deciphera Pharmaceuticals Inc, Duality Biologics, Eisai Inc, Elevar Therapeutics, EMD Serono Inc, Exelixis Inc, Genelux Corporation, Genentech, a member of the Roche Group, Genmab US Inc, GSK, ImmunoGen Inc, Imvax Inc, Incyte Corporation, InterVenn Biosciences, InxMed, Iovance Biotherapeutics, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Laekna Therapeutics, Leap Therapeutics Inc, Luzsana Biotechnology, Merck, Mersana Therapeutics Inc, MSD, Myriad Genetic Laboratories Inc, Novartis, Novocure Inc, Onconova Therapeutics Inc, OncoQuest Inc, Pfizer Inc, Predictive Oncology Inc, Prelude Therapeutics, Regeneron Pharmaceuticals Inc, Replimune, Roche Laboratories Inc, R-Pharm US, Rubius Therapeutics, Seagen Inc, Sorrento Therapeutics, Sumitomo Dainippon Pharma Oncology Inc, Sutro Biopharma, Tarveda Therapeutics, Tesaro, A GSK Company, Toray Industries Inc, Trillium Therapeutics Inc, Umoja Biopharma, VBL Therapeutics, Verastem Inc, Vincerx Pharma, Xencor, Zentalis Pharmaceuticals; Nonrelevant Financial Relationships: Amarex Clinical Research, GOG Foundation, Ludwig Institute for Cancer Research Ltd, National Cancer Institute, NRG Oncology, RTOG Foundation, SWOG.

    Joyce O’Shaughnessy, MD
    Celebrating Women Chair in Breast Cancer Research
    Baylor University Medical Center
    Chair, Breast Disease Committee
    Sarah Cannon Research Institute
    Dallas, Texas

    Advisory Committees and Consulting Agreements: Aadi Bioscience, Agendia Inc, Amgen Inc, Aptitude Health, AstraZeneca Pharmaceuticals LP, BioNTech SE, Bristol Myers Squibb, Daiichi Sankyo Inc, Duality Biologics, Eisai Inc, Ellipses Pharma, Exact Sciences Corporation, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Guardant Health, HiberCell, Jazz Pharmaceuticals Inc, Johnson & Johnson Pharmaceuticals, Lilly, Merck, Mersana Therapeutics Inc, Natera Inc, Novartis, Pfizer Inc, Pierre Fabre, Puma Biotechnology Inc, Roche Laboratories Inc, Sanofi, Seagen Inc, Stemline Therapeutics Inc, Summit Therapeutics, Tempus, TerSera Therapeutics LLC.

    Krish Patel, MD
    Director of Lymphoma Research
    Sarah Cannon Research Institute
    Nashville, Tennessee

    Consulting Agreements: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol Myers Squibb, Caribou Biosciences Inc, Fate Therapeutics, Genentech, a member of the Roche Group, Johnson & Johnson Pharmaceuticals, Kite, A Gilead Company, Lilly, Merck, Nurix Therapeutics Inc, Pfizer Inc; Contracted Research (Funding to Institution): AbbVie Inc, Adaptive Biotechnologies Corporation, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Caribou Biosciences Inc, Century Therapeutics, CRISPR Therapeutics, Fate Therapeutics, Genentech, a member of the Roche Group, Johnson & Johnson Pharmaceuticals, Kite, A Gilead Company, Lilly, Merck, Nurix Therapeutics Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Sana, Xencor.

    Philip A Philip, MD, PhD
    Professor of Oncology and Pharmacology
    Leader, GI and Neuroendocrine Oncology
    Henry Ford Cancer Institute
    Wayne State University
    Detroit, Michigan

    Advisory Committees: Agenus Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Daiichi Sankyo Inc, Gilead Sciences Inc, HUYA Bioscience International, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Novocure Inc, Pfizer Inc, Processa Pharmaceuticals Inc, Seagen Inc, Takeda Pharmaceuticals USA Inc; Contracted Research: Amgen, BioNTech SE, Moderna, Novocure Inc; Data and Safety Monitoring Boards/Committees: Cyclacel Pharmaceuticals Inc, Oncolytics Biotech Inc; Speakers Bureaus: Astellas, Incyte Corporation.

    Kanwal Raghav, MD
    Associate Professor, Gastrointestinal Medical Oncology
    Executive Medical Director (EMD), Ambulatory Treatment Centers
    The University of Texas MD Anderson Cancer Center
    Houston, Texas

    Advisory Committees and Contracted Research: AbbVie Inc, AstraZeneca Pharmaceuticals LP,Daiichi Sankyo Inc, Eisai Inc, Guardant Health, Janssen Biotech Inc, Merck, Pfizer Inc; Data and Safety Monitoring Boards/Committees: AbbVie Inc, Pfizer Inc.

    Richard F Riedel, MD
    Professor of Medicine with Tenure
    Associate Director, Clinical and Translational Research
    Duke Sarcoma Center
    Duke Cancer Institute
    Duke University
    Durham, North Carolina

    Advisory Committees and Consulting Agreements: Aadi Bioscience,Adaptimmune, Bayer HealthCare Pharmaceuticals, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Daiichi Sankyo Inc, Deciphera Pharmaceuticals Inc, GSK, NanoCarrier Co Ltd, Recordati, SpringWorks Therapeutics Inc; Contracted Research: Aadi Bioscience, Adaptimmune, Arog Pharmaceuticals Inc, Ayala Pharmaceuticals, BioAtla, Blueprint Medicines, Cogent Biosciences, Daiichi Sankyo Inc, Deciphera Pharmaceuticals Inc, GSK, Inhibrx, Intensity Therapeutics, NanoCarrier Co Ltd, Oncternal Therapeutics, PTC Therapeutics, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, TRACON Pharmaceuticals Inc, Trillium Therapeutics Inc; Nonrelevant Financial Relationships: SARC (Sarcoma Alliance for Research through Collaboration).

    Kerry A Rogers, MD
    Associate Professor
    Division of Hematology
    The Ohio State University
    Columbus, Ohio

    Advisory Committees: AstraZeneca Pharmaceuticals LP, Janssen Biotech Inc; Consulting Agreements: AbbVie Inc, Alpine Immune Sciences, BeiGene Ltd, Genentech, a member of the Roche Group, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Pharmacyclics LLC, an AbbVie Company; Contracted Research: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Novartis.

    Jonathan E Rosenberg, MD
    Chief, Genitourinary Medical Oncology Service
    Division of Solid Tumor Oncology
    Enno W Ercklentz Chair
    Memorial Sloan Kettering Cancer Center
    New York, New York

    Advisory Committees: Astellas, Seagen Inc, Tyra Biosciences Inc; Consulting Agreements: Aadi Bioscience, Aktis Oncology, Alligator Bioscience, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, EMD Serono Inc, Genentech, a member of the Roche Group, Generate Biomedicines, Gilead Sciences Inc, Hengrui Therapeutics Inc, Imvax Inc, Janssen Biotech Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Pfizer Inc, Samsung Bioepis, Seagen Inc, Tyra Biosciences Inc; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Seagen Inc.

    Simron Singh, MD, MPH
    Professor, University of Toronto
    Susan Leslie Clinic for Neuroendocrine Tumours
    Odette Cancer Centre
    Sunnybrook Health Sciences Centre
    Toronto, Ontario, Canada

    Advisory Committees: Ipsen Biopharmaceuticals Inc, Novartis, Sanofi.

    Brian M Slomovitz, MD
    Professor, OB-GYN, Florida International University
    Director, Gynecologic Oncology
    Co-Chair, Cancer Research Committee
    Mount Sinai Medical Center
    Miami, Florida

    Consulting Agreements: Aadi Bioscience, AstraZeneca Pharmaceuticals LP, Eisai Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, GSK, Incyte Corporation, Merck, Novartis, Regeneron Pharmaceuticals Inc, Seagen Inc.

    Jonathan Strosberg, MD
    Professor
    Moffitt Cancer Center and Research Institute
    Tampa, Florida

    Advisory Committees: Boehringer Ingelheim Pharmaceuticals Inc, Exelixis Inc; Contracted Research: ITM Isotope Technologies Munich SE, RadioMedix Inc, RayzeBio Inc.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, ADC Therapeutics, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Clovis Oncology, Coherus BioSciences, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Hologic Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from ADC Therapeutics, Astellas and Pfizer Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Blueprint Medicines, Bristol Myers Squibb, Daiichi Sankyo Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc and AbbVie Inc, GSK, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Lilly, Merck, Natera Inc, Novartis, Sanofi, SpringWorks Therapeutics Inc, and Stemline Therapeutics Inc.

    Release date: April 2025
    Expiration date: April 2026

    After completing the post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Watch video
(WIFI is recommended for best performance):

Keynote Session: Hormone Receptor-Positive Metastatic Breast Cancer

Module 1: HER2-Positive, Triple-Negative and Localized Breast Cancer

Module 2: Neuroendocrine Tumors

Module 3: Chronic Lymphocytic Leukemia

Module 4: Sarcoma and Other Connective Tissue Neoplasms

Module 5: EGFR Mutation-Positive Non-Small Cell Lung Cancer

Module 6: Gynecologic Cancers

Module 7: Prostate Cancer

Module 8: Biliary Tract Cancers

Module 9: Non-Hodgkin Lymphoma

Module 10: Colorectal Cancer

Module 11: Urothelial Bladder Cancer

Module 12: Multiple Myeloma

Module 13: Hepatocellular Carcinoma

Module 14: Systemic Mastocytosis and Myelofibrosis

Module 15: Immunotherapy and Other Nontargeted Approaches for NSCLC

Module 16: Pancreatic Cancer

Module 17: Gastroesophageal Cancer

Select Publications